Plus   Neg

Stock Alert: BioNTech Shares Up On CHMP Positive Opinion For Pfizer-BioNTech COVID-19 Vaccine

Shares of BioNTech SE (BNTX) are rising over 2% Monday morning, after the company and Pfizer Inc. (PFE) announced that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA issued a positive opinion to recommend the conditional marketing authorization or CMA of the Pfizer-BioNTech COVID-19 Vaccine - also known as BNT162b2, for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older.

Key Takeaways From the Press Release:

* European Commission decision on conditional marketing authorization expected imminently.

* Positive CHMP opinion follows several emergency use authorizations worldwide; committee reviewed totality of scientific evidence, including Phase 3 efficacy and safety data.

* If authorized, BNT162b2 will be the first COVID-19 vaccine available in the European Union.

BioNTech shares, which have been trading between $28.00 and $131.00 for the past one year, are currently trading at $106.73, up $2.49 or 2.39%. Trading volume is rising over 713K versus an average volume of 3.85 million shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT